BEIJING : China's CanSino Biologics said on Tuesday it had not started enrolling participants for a late-stage trial of its potential COVID-19 vaccine Ad5-nCoV.Russian pharmaceutical company Petrovax said in a statement on Saturday that it would run the trial for CanSino in Russia.Russia's state register for clinical trials showed that a Phase 3 study began on Friday.
Some 625 people are expected to be recruited to test the safety and effectiveness of the drug.CanSino said in a filing on Tuesday that the company was working with several countries to start Phase 3 trials as soon as possible."As at the date of this announcement, enrolment of phase III clinical trial has not started," it said.China has already approved the vaccine for use by.